Adjunctive Therapies to Optimize Closed-loop Glucose Control. (November 2021)

• Record Type: Journal Article
• Authors: Srinivasan, Shylaja; Ekhlaspour, Laya; Cengiz, Eda
• Is Part Of: Journal of diabetes science and technology. Volume 15:Number 6(2021)
• Page Start: 1243
• Page End: 1251
• Publication Date: 2021-11
• Subjects: closed-loop system -- artificial pancreas -- adjunctive therapy -- insulin -- glucagon -- GLP-1 agonist; Diabetes -- Periodicals; Medical technology -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462005
• DOI: 10.1177/19322968211032701
• Languages: English
• ISSNs: 1932-2968

Abstract

Closed-loop insulin delivery systems are fast becoming the standard of care in the management of type 1 diabetes and have led to significant improvements in diabetes management. Nevertheless, there is still room for improvement for the closed-loop systems to optimize treatment and meet target glycemic control. Adjunct treatments have been introduced as an alternative method to insulin-only treatment methods to overcome diabetes treatment challenges and improve clinical and patient reported outcomes during closed-loop treatment. The adjunct treatment agents mostly consist of medications that are already approved for type 2 diabetes treatment and aim to complete the missing physiologic factors, such as the entero-endocrine system, that regulate glycemia in addition to insulin. This paper will review many of these adjunct therapies, including the basic mechanisms of action, potential benefits, side effects, and the evidence supporting their use during closed-loop treatment.